# EFFICACY AND SAFETY OF ENDOSCOPIC ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION OF PANCREATIC TUMORS - INITIAL EXPERIENCE OF SINGLE CENTER

Anastazija Petreska

UEG Week Vienna 2024 | Poster

Pancreas

October 13, 2024

**A single-center retrospective study of 10 EUS-guided radiofrequency ablation sessions in 7 patients with pancreatic tumors reported 85.71% clinical success at 6-month follow-up with no adverse events.**

## KEY POINTS

- Seven patients with pancreatic tumors (5 neuroendocrine tumors including 3 insulinomas, 1 renal cell carcinoma metastasis, 1 ductal adenocarcinoma) underwent 10 EUS-guided RFA sessions between August 2022 and December 2023.
- Clinical success, defined as complete disappearance of lesions on imaging at 3 and 6 months, was achieved in 85.71% of patients; three patients required a second session at 3 months due to signs of vital tissue.
- A negative correlation was found between lesion size and response rate, while no correlation was observed between response and functional status of neuroendocrine tumors or lesion location.
- Insulinoma patients experienced resolution of hormonal hypersecretion symptoms within 24 hours post-procedure with no hypoglycemia events, and no early or late adverse events were reported in any patient.
- Authors conclude EUS RFA may be offered to selected patients as an alternative to surgery for pancreatic neuroendocrine tumors and note potential as adjunctive palliative treatment for locally advanced adenocarcinoma, though more data are needed.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/0c48086a-9111-11ef-b66c-0242ac140004

**AI-generated summary**

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.